Since our in vitro and in vivo studies have established the roles of CCR7/CCL21 and VEGFR3/VEGF-C axes in breast cancer induced lymphangiogenesis, we have postulated that CCR7 and VEGF-C expressions will be noticeably different in tumor tissues when compared to their non-tumor counterparts. The gene discussed is CCL21; the disease is neoplasm.